Citation Impact
Citing Papers
Prospective identification of tumorigenic breast cancer cells
2003 Standout
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1998
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
2006
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
2014
Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
2015
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Cancer statistics, 2017
2017 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Cancer Statistics, 2021
2021 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
1995
Induction and potential biological relevance of a Ca2+‐independent nitric oxide synthase in the myocardium
1992
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment
2005
Global Cancer Statistics, 2002
2005 Standout
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
1993
Drug development and clinical trials—the path to an approved cancer drug
2012
Endometriosis
2009 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Racial Disparities in the Quality of Care for Enrollees in Medicare Managed Care
2002
Renal-Cell Carcinoma
1996 Standout
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
1993
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Survival of Blacks and Whites After a Cancer Diagnosis
2002
Tumor metastasis: moving new biological insights into the clinic
2013
Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group
2008
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
2002 Standout
Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
1995
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
2013
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Global cancer statistics
2011 Standout
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
2003
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Primary Care Physicians Who Treat Blacks and Whites
2004 Standout
Participation in Cancer Clinical Trials
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival
2004
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
The “All of Us” Research Program
2019 Standout
Raise standards for preclinical cancer research
2012 StandoutNature
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
2017
The L-Arginine-Nitric Oxide Pathway
1993 Standout
Malignant Gliomas in Adults
2008 Standout
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2005 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis
2011 Standout
Head and Neck Cancer
1993 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Does tumour dormancy offer a therapeutic target?
2010
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.
1992
Guideline implementation for breast healthcare in low-income and middle-income countries
2008
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Anemia of Chronic Disease
2005 Standout
Comorbidity and Survival Disparities Among Black and White Patients With Breast Cancer
2005
Racial/Ethnic Disparities in Time to Follow-Up after an Abnormal Mammogram
2008
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
2000
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
2011
Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
2008
Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
2006
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
2000
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
1993
Reanalysis and Results after 12 Years of Follow-up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer
1995
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein
1992
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Cancer statistics, 2016
2016 Standout
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Weight Loss in Breast Cancer Patient Management
2002
Metabolic reprogramming and cancer progression
2020 StandoutScience
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
A New Initiative on Precision Medicine
2015 Standout
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
2017
Global cancer statistics, 2012
2015 Standout
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
2006
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
2007
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
1998
Works of Jeffrey S. Abrams being referenced
National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network
2014
Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
2010
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
1995
Race and Differences in Breast Cancer Survival in a Managed Care Population
1999
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
2008
Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy
1989
Much Ado About Not ... Enough Data: High-Dose Chemotherapy With Autologous Stem Cell Rescue for Breast Cancer
1998
The National Cancer Institute Audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06
1995
Adjuvant therapy for breast cancer — results from the USA consensus conference
2001
A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.
1989
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
1995
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.
1993
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
2005
Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians
2002
Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
2008
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
2011
Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741
1999
Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
2007
Cisplatin for small-cell lung cancer.
1989
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
2002
High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell Carcinoma
1990
A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
2004